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Abstract. The present study evaluated the efficacy of droz-
itumab, a human monoclonal agonistic antibody directed 
against death receptor 5 (DR5), as a new therapeutic avenue 
for the targeted treatment of bone and soft-tissue sarcomas. 
The antitumour activity of drozitumab as a monotherapy or 
in combination with Nutlin-3a was evaluated in a panel of 
sarcoma cell lines in vitro and human sarcoma patient samples 
ex vivo. Knockdown experiments were used to investigate the 
central role of p53 as a regulator of drozitumab cytotoxicity. 
Pre-activation of the p53 pathway through Nutlin-3a upregu-
lated DR5, subsequently sensitising sarcoma cell lines and 
human sarcoma specimens to the pro-apoptotic effects of 
drozitumab. Silencing of p53 strongly decreased DR5 mRNA 
expression resulting in abrogation of drozitumab-induced 
apoptosis. Our study provides the first pre-clinical evaluation 
of combination therapy using p53-activating agents with droz-
itumab to further sensitise sarcomas to the cytotoxic effects of 
DR5 antibody therapy.
Introduction
Sarcomas represent a diverse group of heterogeneous mesen-
chymal neoplasms that affect ~200,000 individuals worldwide 
each year. There has been limited improvement in overall 
5-year survival rates for sarcoma patients over the past 30 
years, particularly for patients with metastatic disease. As such, 
the use of molecular-targeted therapies has emerged as a prom-
ising new therapeutic approach for the treatment of sarcomas. 
Activation of the extrinsic pathway of apoptosis through 
the use of recombinant ligand and agonistic monoclonal anti-
bodies directed against TRAIL receptors DR4 (TRAIL-R1) 
and/or DR5 (TRAIL-R2) has been explored as a promising new 
targeted therapy for numerous types of malignancies. Based 
on their selective ability to induce apoptosis in a variety of 
human cancer cell lines and xenografts while sparing normal 
cells (1), several agents are currently undergoing phase I and 
II clinical testing both as single agents and in combination 
with traditional chemotherapies. These include monoclonal 
agonistic antibodies which specifically target either DR5, 
drozitumab (Genetech) (2), lexatumumab (Human Genome 
Sciences) (3-6), conatumumab (Amgen) (7-10), tigatuzumab 
(humanized IgG1 antibody; Daiichi-Sankyo) and LBY135 
[chimeric (mouse/human) IgG1 antibody; Novartis] (11) or 
DR4, mapatumumab (Human Genome Sciences) (12-17) or 
both cognate receptors as well as three decoy receptors of 
recombinant human TRAIL (rhApo2L/TRAIL) (dulanermin, 
Amgen/Genentech) (18).
Results from early trials have established that DR4 and 
DR5 agonistic antibodies can be considered safe and are well 
tolerated with responses not limited to histological subtype. 
However, the clinical efficacy of these agonistic antibodies as 
monotherapeutic agents has proven to be quite poor, with only 
a few patients showing partial or complete responses (19). Out 
of the 41 evaluable patients who participated in dose escala-
tion phase I clinically testing of drozitumab, partial responses 
were reported in only 3 patients (chondrosarcoma, colorectal 
cancer and ovarian cancer) (2). These findings reflect cell 
culture studies which indicate that only a small subset of 
sarcoma cell lines are highly sensitive to DR5 agonistic anti-
bodies (20-23).  
The poor clinical efficacy of drozitumab as a monotherapy 
warrants further investigation into combinational therapeutic 
approaches involving drozitumab with other systemic thera-
pies to synergistically drive tumour regression. Furthermore, 
additional mechanistic studies are required to completely 
delineate the fundamental regulators of drozitumab. A broad 
spectrum of apoptosis regulatory molecules (FLIP, XIAP 
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and Bcl-XL) and signalling pathways (NF-κB and Akt) 
are believed to confer resistance; however, little is known 
concerning the influence of proteins which sensitise tumour 
cells to drozitumab therapy, apart from DR5 itself. The protein 
and mRNA expression levels of DR5 and DR4 in sarcoma cell 
lines have been extensively documented in literature. Notably, 
resistance to TRAIL-mediated apoptosis is not associated 
with differential expression of TRAIL-receptors between 
sensitive and resistant sarcoma cell lines (24,25). As DR5 has 
been shown to be a transcriptional target of p53 (26), this study 
assessed the role of p53 in mediating sensitivity to drozitumab 
in sarcoma cell lines and human sarcoma patient material. 
As expected, knockdown of p53 ablated drozitumab-induced 
apoptosis in vitro. Furthermore, pre-activation of the p53 
pathway through Nutlin-3a (p53-MDM2 antagonist) enhanced 
the cytotoxic effects of drozitumab both in vitro and ex vivo. 
Our study provides the first pre-clinical evidence that pre-
activation of the p53 pathway in conjunction with drozitumab 
will potentially provide an effective therapeutic means to 
maximise the apoptotic response from both the extrinsic and 
intrinsic pathway for the treatment of sarcomas.
Materials and methods
Cell culture. Osteosarcoma (Saos-2, U20S) and Ewing's 
sarcoma (SK-ES1, RD-ES) cell lines were purchased from 
American Type Tissue Culture (ATCC, Manassas, VA, USA). 
Additional Ewing's sarcoma cell lines CADO-ES1, STA-ET1, 
SK-N-MC, TC252, VH-64, WE-68 were kindly supplied 
by J. Sonnemann (Department of Pediatric Haematology 
and Oncology, University Children's Hospital, Jena, 
Germany), P. Ambros (Children's Cancer Research Institute, 
St. Anna Children's Hospital, Vienna, Austria), V. Russo 
(Murdoch Children's Research Institute, Royal Children's 
Hospital, Victoria, Australia), G. Hamilton (Department 
of Surgery, University of Vienna, Austria) and F. van Valen 
(Department of Orthopaedic Surgery, Westfälische Wilhelms 
University, Germany). Cell lines were cultured as previously 
described (27).
Cell viability assays. Cells were seeded in 96-well microtiter 
plates at a density of 3x104 cells/well in the presence of droz-
itumab + anti-Fcγ at the indicated concentrations for 24 h. 
Drozitumab (a kind gift from Dr Avi Ashkenazi, Genentech 
Inc., South San Francisco, CA, USA), was cross-linked with 
anti-human IgG Fcγ antibody (Jackson ImmunoResearch 
Laboratories, Inc., West Grove, PA, USA) as previously 
described (28). For synergy experiments, cells were pre-treated 
with Nutlin-3a (Cayman Biochemicals, Ann Arbor, MI, USA) 
for 24 h prior to the addition of drozitumab + anti-Fcγ. Cells 
were harvested and processed as previously described (27). 
The viability of harvested cells was determined using 7-amino-
actinomycin-D staining and processed on a FACSCalibur flow 
cytometer (Becton-Dickinson Immunocytometry Systems, 
Franklin Lakes, NJ, USA).
RNA interference. Cell lines with silenced expression of p53 
were generated using the pGIPZ lentiviral shRNAmir system 
(Open Biosystems) as previously described (29). Briefly, 
HEK-293T cells were seeded at 50% confluency and trans-
fected with either a non-silencing scramble control (RHS4346) 
or shRNA directed against human p53 (V2LHS217) using 
Trans-Lentiviral packaging mix according to the manufac-
turer's protocol (Thermo Fisher Scientific, Waltham, MA, 
USA). Forty-eight hours post-transfection, growth medium 
containing lentivirus particles was filtered and added to 
recipient TC252 cells seeded at 50% confluency. Polyclonal 
populations of transduced cells were generated through subse-
quent puromycin selection
Western blot analysis. Western blot analysis was performed 
as previously described (30). Protein extracts were resolved 
by SDS polyacrylamide gel electrophoresis on 8% polyacryl-
amide gels and incubated with anti-p53 DO-1 (1:1,000, Santa 
Cruz Biotechnology, Santa Cruz, CA, USA). Anti-β-actin 
(1:2,000; Sigma Aldrich, St. Louis, MO, USA) was used as an 
internal loading control. 
Real-time PCR. Total RNA was extracted using RNeasy Mini 
kit (Qiagen), using On-Column RNase-free DNase digestion 
according to the manufacturer's instructions. cDNAs were 
generated and real-time PCR reactions were processed and 
normalised as previously described (31). Primer sequences are 
listed in Table I. 
Table I. Primer sequences utilised in this study.
 Primer sequence 5'→3' --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
 Forward Reverse
PPIG (housekeeping) CAGATGCAGCTAGCAAACCGTTTG CTCTTCAGTAGCACTTTCGGAATCAGAGG
DR5 (TRAIL-R2) CGCTGCACCAGGTGTGATT GTGCCTTCTTCGCACTGACA
p21 (CDKN1A) TGGACCTGGAGACTCTCAGGGTCG TTAGGGCTTCCTCTTGGAGAAGATC
PUMA (BBC3) ACGACCTCAACGCACAGTACG TCCCATGATGAGATTGTACAGGAC
p53 exons 2-4 GTGTCTCATGCTGGATCCCCACT GGATACGGCCAGGCATTGAAGT
p53 exons 5-6 TGCAGGAGGTGCTTACGCATGT CCTTAACCCCTCCTCCCAGAGAC
p53 exons 7-9 ACAGGTCTCCCCAAGGCGCACT TTGAGGCATCACTGCCCCCTGAT
p53 exon 10 GTCAGCTGTATAGGTACTTGAAGTGCAG TGGCAGCTGAGCTAGACCTCG
p53 exon 11 CCTTAGGCCCTTCAAAGCATTGGTCA GTGCTTCTGACGCACACCTATTGCAAG
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Explant system. The ex vivo sarcoma tissue explant system 
was adapted from methods previously described (32). Briefly 
sarcoma tissue from patients previously not exposed to neo-
adjuvant therapy was collected immediately following surgical 
resection and treated with the following: vehicle control 
(DMSO), Nutlin-3a (10 µM), drozitumab as a monotherapy 
(200 ng/ml) and in combination with Nutlin-3a (10 µM) for 
48 h. For synergy experiments, explants were pre-treated with 
Nutlin-3a for 24 h prior to the addition of drozitumab + anti 
Fcγ. Paraffin-embedded sections were subjected to immuno-
histochemical (IHC) analysis for activated-caspase 3 (ab4051, 
1:100; Abcam, Cambridge, UK). IHC analysis was adapted 
from methods previously described (32). Sequencing of exons 
2-11 of the TP53 gene was conducted to confirm the p53 status 
of the sarcoma tissue. 
Ethical approval. This study was performed with the approval 
of the Royal Adelaide Hospital Human Research Ethics 
Committee (protocol #100505). The research conducted 
throughout is compliant with the Helsinki Declaration and 
adheres to the guidelines stated by the National Health and 
Medical Research Council (NHMRC) of Australia.
Statistics. Combination index (CI) values were used to deter-
mine the effects of drozitumab on cell viability in the presence 
and absence of Nutlin-3a, as previously described (33). A CI of 
1 indicates an additive effect; >1, an antagonistic effect; and 
<1, a synergistic effect.
Results and Discussion
In an effort to define the role of p53 in the cytotoxic response 
of sarcoma cells to drozitumab, lentiviral-based delivery of 
shRNAs targeting p53 (or non-targeting control shRNAs) 
were delivered into the wild-type p53 Ewing's sarcoma cell 
line TC252. Knockdown of p53 resulted in effective ablation 
of p53 protein levels (Fig. 1). The sensitivity of these TC252 
derivatives expressing either p53 shRNA or control shRNA 
to drozitumab was subsequently determined. In the control 
(non-silencing shRNA) cell line derivative, drozitumab 
induced a dose-dependent increase in cytotoxicity, with an 
IC50 of 54 ng/ml (Fig. 2A). In contrast, silencing of p53 signifi-
cantly ablated the ability of drozitumab to induce apoptosis 
(IC50 >1,000 ng/ml). Even at the maximum concentration 
tested (1,000 ng/ml), drozitumab was only able to induce 22% 
cell death (Fig. 2B). As DR5 is a p53-regulated gene (26), we 
wished to confirm that this observed ablation in drozitumab-
induced cytotoxicity was attributed to reduced DR5 expression. 
Activation of the p53 pathway was achieved through the use 
Figure 1. Knockdown of p53 in TC252 cells. Western blot analysis of p53 
expression in TC252 non-silencing and p53 shRNA cell lines. Total β-actin 
level was used as a protein loading control. 
Figure 2. Knockdown of p53 ablates the cytotoxic effects of drozitumab. 
(A) TC252 non-silencing and (B) p53 shRNA cell lines were treated with 
increasing concentrations of drozitumab (0-1,000 ng/ml) for 24 h. Cell 
viability was determined by 7AAD staining and analysed by flow cytometry 
(triplicate reactions). The percentage of cell death (means ± SE) for each 
treatment is shown.
Figure 3. DR5 expression is p53 dependent. TC252 non-silencing and p53 
shRNA cell lines were treated with Nutlin-3a (0, 5 and 10 µM) for 8 h. RNA 
was extracted from cells, with relative target DR5 mRNA expression levels 
determined by RT-PCR analysis. Data represent means ± SE from triplicate 
reactions. ***P<0.0001, statistical significance as determined by unpaired 
two-tailed t-test.
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of the non-genotoxic agent Nutlin-3a. Indeed, significant DR5 
upregulation was observed following Nutlin-3a treatment 
of control (non-silencing shRNA) TC252 cells. In contrast, 
TC252 cells expressing the p53-specific shRNA were associ-
ated with a significantly diminished capacity to upregulate 
DR5 upon p53 activation (P<0.0001) (Fig. 3). These results 
suggest that p53-induced expression of DR5 is required for 
conferring drozitumab sensitivity.
As Nutlin-3a treatment upregulated DR5 mRNA expres-
sion in a p53-dependent manner, we sought to determine 
whether pre-activation of the p53 pathway with Nutlin-3a 
augments drozitumab induced apoptosis in vitro. WE-68 or 
TC252 sarcoma cell lines were pre-treated with Nutlin-3a 
for 24 h before the addition of drozitumab for an additional 
24 h. This combined dose and schedule of Nutlin-3a and 
drozitumab resulted in synergistic cell death, with maximum 
combination indices of ~0.5 in both cell lines (Fig. 4, Table II). 
Furthermore, synergism between these two agents was only 
Figure 4. Nutlin-3a enhances the apoptotic response to drozitumab. (A) WE-68 and (B) TC252 cells were pre-treated with Nutlin-3a (0-5 µM) for 24 h, prior to 
the addition of drozitumab (concentrations as indicated) for a further 24 h. Cell viability was determined by 7AAD staining and analysed by flow cytometry. 
The percentage of cell death for each treatment is shown. 
Table II. Combination index (CI) values.
 In combination with Nutlin-3a ---------------------------------------------------------------
 Drozitumab Drozitumab dose Combination
Cell line IC50 (ng/ml) (ng/ml) index
WE-68 1.5±0.8 0.31 0.62
  0.62 0.54
  1.25 0.87
TC252 40.7±2.2 3.9 0.96
  7.8 0.57
  15.6 0.52
  31.2 0.79
CI <1, CI =1 and CI >1 indicate synergism, additive effect and antago-
nism, respectively.
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achieved in the wild-type p53 cell lines WE-68 and TC-252 
but not in the mutant p53-expressing cell line SK-ES1 (Fig. 5). 
Importantly, the viability of normal human fibroblasts was 
unaffected following exposure to drozitumab at these concen-
trations (Fig. 6).
We subsequently investigated whether Nutlin-3a augments 
the apoptotic response of drozitumab in human sarcoma 
patient samples ex vivo. Sarcoma tissues from 3 patients were 
collected immediately following surgical resection, dissected 
in 1-mm3 pieces and pre-treated using an ex vivo tissue 
explant system with Nutlin-3a (10 µM) for 24 h prior to the 
addition of drozitumab (200 ng/ml) for a subsequent 24 h. An 
increased level of apoptosis following this combination treat-
ment was achieved in 1 of the 3 patients (patient 1; malignant 
fibrous histiocytoma) (Fig. 7A). This response was associated 
with a significant upregulation of DR5 receptor expression 
Figure 5. Synergy between Nutlin-3a and drozitumab is dependent on p53. Mutant p53 cell line SK-ES1 was pre-treated with Nutlin-3a (0-10 µM), prior to the 
addition of drozitumab (0-500 ng/ml) for a further 24 h. Cell viability was determined by 7AAD staining and analysed by flow cytometry. The percentage of 
cell death for each treatment is shown.
Figure 6. Drozitumab treatment does not affect normal cells. Normal human 
fibroblasts were treated with increasing concentrations of drozitumab 
(0-1,000 ng/ml) for 24 h. Cell viability was determined by 7AAD staining 
and analysed by flow cytometry. The percentage of apoptotic cells is shown. 
Figure 7. Nutlin-3a synergises with drozitumab in human sarcoma patient 
samples ex vivo. (A) Sarcoma tissue from 3 patients were treated as follows: 
Nutlin-3a alone (10 µM, 48 h), drozitumab alone (200 ng/ml, 24 h), or pre-
treated with Nutlin-3a (10 µM) for 24 h before the addition of drozitumab 
(200 ng/ml) for an additional 24 h. The percent change in apoptotic cells 
from the vehicle control was evaluated by immunohistochemical analysis for 
activated-caspase 3. (B) Relative DR5 mRNA expression levels (fold- induc-
tion) from sarcoma explants treated with vehicle control or Nutlin-3a (10 µM) 
for 24 h were determined by RT-PCR analysis. ***P<0.0001, statistical signifi-
cance. Data represent means ± SE from triplicate reactions. 
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(P<0.0001) following Nutlin-3a treatment, thus, providing 
a plausible mechanism for this enhanced apoptotic response 
(Fig. 7B). In contrast, sarcomas from patients 2 and 3 showed 
neither an increase in drozitumab efficacy upon pre-treatment 
with Nutlin-3a, nor DR5 upregulation following Nutlin-3a 
pre-treatment. Furthermore, the ability of this combina-
tion treatment to induce the expression of other verified p53 
target genes (p21 and PUMA) was also only observed in the 
responding patient (patient 1) (Fig. 8). Therefore, the ability of 
p53 to stimulate DR5 expression in sarcoma tissues is a key 
factor that contributes towards the synergistic effects between 
p53 activators and drozitumab.
To further investigate the role of p53 in modulating 
susceptibility of sarcoma cell lines to the cytotoxic effects of 
drozitumab, viability assays were carried out on a panel of 
10 sarcoma cell lines with varying p53 statuses in vitro. Notably, 
there was no significant correlation between p53 status of the 
sarcoma cell lines and sensitivity to drozitumab (Table III), 
suggesting that p53 status alone is not an indispensable deter-
minant for driving drozitumab sensitivity. In particular, two of 
the wild-type p53 sarcoma cell lines (CADO-ES1 and U2OS) 
were completely resistant to drozitumab (IC50 >1,000 ng/ml). 
However, it must be noted that the Ewing's sarcoma cell line 
CADO-ES1 is deficient in caspase-8 expression, an essential 
protein required for the initiation of the extrinsic pathway of 
apoptosis (34). In summary, although p53 may play a critical 
role in drozitumab sensitivity in sarcomas that have retained 
a wild-type p53, our data suggest that the p53 status of cell 
lines alone is not enough to predict drozitumab cytotoxicity, 
most likely due to secondary genetic alterations in the tumour 
that drive fundamental defects in the apoptotic pathway. Thus, 
further mechanistic studies are required to define other factors 
that can influence the susceptibility of sarcomas to droz-
itumab-mediated apoptosis. Collectively, our results justify 
further pre-clinical investigations of therapeutic regimes that 
combine DR5 agonists with p53 activators as a new means to 
amplify crosstalk signals from both the extrinsic and intrinsic 
pathways of apoptosis for the targeted treatment of sarcoma.
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